Benchling’s Post

The time has come to propel mRNA Vaccine Manufacturing to rocket speed with Piperidine-based Ionizable Lipid Nanoparticles. Now is the time to accelerate your mRNA-based therapeutic manufacturing. Harness the power of piperidine-based ionizable lipids to create superior LNPs and pair them with your desired mRNAs. Don't wait, seize the opportunity to revolutionize mRNA based therapeutics. #mRNAdelivery #lipidnanoparticles #ionizablelipids #drugdelivery #nanotechnology #pharmaceuticalresearch #biotechnology #lipidchemistry #mRNAtherapeutics #drugdevelopment

Are you working on bispecific antibody therapeutics? Are you using Knobs-Into-Holes or a common light chain or other approach? Are you experiencing any challenges with efficiency, expression or purification of your bsAb? Do you just want to learn more about what is a bispecific antibody and how or why they are important therapeutics? I hope you will take 4-minutes and 14-seconds from your day and watch our new #bYlok solution video about how Lonza can help solve the HC-LC mis-pairing problem with bsAbs. #lonza #bispecifics #bispecificantibodies #solutions #biotechnology https://lnkd.in/gPXx5FwK

Join Advancing RNA, featuring insights from pros like Greg Troiano at Sanofi and April Sena, PhD from Life Edit Therapeutics as we dive into the nitty-gritty of the inbound supply chain for mRNA/LNP therapeutics. Expect in-depth discussions on spotting supply gaps, teaming up for better raw materials, picking the right suppliers, and nailing GMP principles to amp up quality and cut costs. We unpack the challenges and wins in the ever-evolving supply chain for both small- and large-scale RNA therapeutics. #AdvancingRNA #mrna #supplychain https://lnkd.in/e2JxQxqG

The second day of Antibody Engineering & Therapeutics Europe in London has just started! 🧬✨ If you’re attending, come and visit Bioassay GmbH at booth #7. We will be happy to discuss with you how can we help you with your bioanalytical needs to move forward your antibody clinical pipeline. #AntibodyEngineering #Therapeutics #Biotech #PotencyAssays #Conference #Bioassay #ReactionBiology

Propel your #mRNA program’s development journey by leveraging our more than 15 years’ experience and expertise in pre-clinical mRNA manufacturing. As part of our globally integrated #CTDMO capabilities, our “mRNA Center of Excellence” expedites your #DrugDevelopment journey, providing services including mRNA #ProcessDevelopment, mRNA #AnalyticalDevelopment, mRNA #Synthesis to Purification of the final mRNA #DrugSubstance. Our “Custom mRNA Synthesis Service” delivers high quality mRNA for all stages, from Pre-Clinical, Early Clinical to Late Clinical and Commercial. We provide flexible research grade mRNA packages from Mg to Gram quantities, to double digit Gram “GMP mRNA drug Substance Batches” supporting first in human studies to late clinical and commercial applications. We provide flexible capacity for your needs - whether you tech transfer your process, or leverage our proprietary PCR-based, scalable, GMP mRNA process platform for achieving high product yields and exceptional quality for your individual mRNA sequence. You can now request your Custom Research grade mRNA” quote directly from “Our Website” through our new mRNA creator! https://lnkd.in/gxy8S_ZA Join us in shaping the future of mRNA-based therapeutics. #mRNA #CTDMO #DrugDiscovery #Medicine #Clinicaltrials #Clinicalresearch #Clinicalstudies #Innovation

A beacon of precision in the dynamic world of biologics, STAT3 Monoclonal Antibody has been placed. Our STAT3 Monoclonal Antibody stands as a testament to innovation, designed to revolutionize therapeutic approaches by precisely targeting key signaling pathways. Elevate your research and therapeutic strategies with the unparalleled specificity and efficacy of our major discovery antibody. Excited to backpack on the transformative journey with GeNext Genomics, where breakthroughs become a reality. Explore the limitless potential of the STAT3 Monoclonal Antibody and witness the future of precision medicine unfold. . To Read More - https://lnkd.in/gXAd9Ace #GeNextGenomics #HighQualityBiologics #MonoclonalAntibody #STAT3Antibody #PrecisionMedicine 

TTP's drying tech could simplify mRNA vaccine storage and transportation. Our gentle, ultra-fast process creates a stable, inhalable dry powder that eliminates the need for freezers, making vaccines more accessible. Want to know more? Steve Taylor and I are presenting a poster at the 4th mRNA-Based Therapeutic Summit in Boston, July 30-31. World RNA Series, #mRNA, #mRNATherapeutics, #mRNAVaccines, #WorldRNA, #mRNASummit

Are you attending Antibody Therapeutics Xchange in Philadelphia on March 26? Don’t miss our Spotlight Presentation, where Julia Su, Ph.D., will present “Innovative Platforms for Rapid and Cost-Effective HTP Antibody & Protein Production.” Discover how our HTP antibody and protein production platforms—Ultra 96+, 777, Quick ‘n’ Clean, Mini Protein Line and T Cell Mate, all powered by our ultra-high titer transient CHO system—are designed for rapid, cost-effective HTP production across various drug targets, from mAb to bsAb to new modalities like mini proteins and soluble TCRs. Register Now : ➡️https://lnkd.in/eUqXWGMe #proteinproduction #drugdiscovery #drugdevelopment #antibodydiscovery #antibodytherapeutics #Therapeutics #WuXibiologics #HubxChange

Join us on February 21, 2024, at 11 AM EST for an insightful discussion on the current state and growth opportunities in the mRNA supply chain. Our Editorial & Community Director, Anna Rose Welch, will be hosting Greg Troiano and April Sena, PhD, industry experts from Sanofi and Life Edit Therapeutics. Together, they'll explore supply chain considerations, identify gaps, and discuss how innovators and suppliers can collaborate to enhance the availability and quality of raw materials for improved mRNA production. Save the date and stay tuned for a deep dive into the world of RNA therapeutics!  https://lnkd.in/gmqnrkaP  #mrna #supplychain #rawmaterials 

BREAKING - New Arcturus Therapeutics ARCT-154 Replicon Injection (self-amplifying mRNA) trial data released. 5 deaths occurred among the injected in study phase 3b. Injected participants experienced a 90% adverse event rate (74.5% systemic - 15.2% required medical attention) after the first dose in study phases 1, 2, and 3a combined. Many of the authors are full time employees of Arcturus Therapeutics. Thus, the study conclusions are more likely to be biased. ARCT-154 is already approved for adults in Japan... https://lnkd.in/eHwZqdex Nicolas Hulscher, MPH